Trial reportIndian journal of ophthalmology2022
Effect of atropine 0.01% on progression of myopia.
Trial report in Indian journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- A systematic review of the study design and statistical practices in randomized controlled trials on myopia treatment (2019-2023).BMC ophthalmology · 2025Pooled it
- Interventions for myopia control in children: a living systematic review and network meta-analysis.The Cochrane database of systematic reviews · 2025Pooled it
- Efficacy and safety of different atropine regimens: MOSAIC2.Annals of translational medicine · 2026Article
- Relationship of Atropine in Controlling Myopia Progression Among Pediatric Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Effectiveness of Low-Dose Atropine (0.01% to 0.05%) in Reducing Myopia Progression: A Systematic Review and Meta-Analysis.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- IMI-Interventions for Controlling Myopia Onset and Progression 2025.Investigative ophthalmology & visual science · 2025Review
- Myopia Control: Are We Ready for an Evidence Based Approach?Ophthalmology and therapy · 2024Review
- Retardation of myopia by atropine regimes.International journal of ophthalmology · 2024Review
- Effectiveness of various atropine concentrations in myopia control for Asian children: a network meta-analysis.Frontiers in pharmacology · 2024Article
- Comparisons of Three Methods for Myopia Control in Adolescents.Journal of ophthalmology · 2022Article
- A Longitudinal Study Evaluating the Impact of 0.01% Atropine in High Myopic Children (RAMCOM-II Study).Journal of current ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Myopia is the most common type of refractive error and the leading cause of functional visual loss. Increased risk of myopic maculopathy, retinal detachment, glaucoma and cataract has been seen with a myopia of as low as -1D. This study was done to determine the effect of atropine 0.01% eye drops on the progression of myopia in children >5 years. Methods: This was a single-blind, prospective, randomized case-control study which included children of 5-15 years with myopia of >2D and were divided into treatment group (group 1) and placebo group (group 2). Children under treatment group were treated with application of 0.01% atropine at night. Children with history of any ocular surgery, chronic ophthalmic illness, squint and amblyopia were excluded from the study. The follow-up for myopia progression was done for two years. Results: This study showed a significant difference in increase of spherical equivalent and axial length among treatment and placebo groups after a duration of two years. Total duration of follow up was twenty-four months. Mean increase in axial length of group 1 and 2 was 0.115 mm and 0.32 mm, respectively. Mean increase in refraction of groups 1 and 2 was -0.30 D and -0.88 D, respectively, showing significant change in axial length and refraction (P < 0.0001). Conclusion: This study supports the use of atropine 0.01% eye drops in reducing the progression of myopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.